These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 36442615)
1. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB Hirsch S; Hinden L; Naim MB; Baraghithy S; Permyakova A; Azar S; Nasser T; Portnoy E; Agbaria M; Nemirovski A; Golomb G; Tam J J Control Release; 2023 Jan; 353():254-269. PubMed ID: 36442615 [TBL] [Abstract][Full Text] [Related]
2. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice. Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396 [TBL] [Abstract][Full Text] [Related]
3. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake. Cooper ME; Regnell SE Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341 [TBL] [Abstract][Full Text] [Related]
4. The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease. Jorgačević B; Vučević D; Vesković M; Mladenović D; Vukićević D; Vukićević RJ; Todorović V; Radosavljević T Can J Physiol Pharmacol; 2019 Feb; 97(2):120-129. PubMed ID: 30673308 [TBL] [Abstract][Full Text] [Related]
8. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats. Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336 [TBL] [Abstract][Full Text] [Related]
9. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003 [TBL] [Abstract][Full Text] [Related]
10. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803 [TBL] [Abstract][Full Text] [Related]
12. Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity. Han JH; Shin H; Rho JG; Kim JE; Son DH; Yoon J; Lee YJ; Park JH; Song BJ; Choi CS; Yoon SG; Kim IY; Lee EK; Seong JK; Kim KW; Kim W Diabetes Obes Metab; 2018 Sep; 20(9):2179-2189. PubMed ID: 29740969 [TBL] [Abstract][Full Text] [Related]
13. Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin. Hussien NI; El-Kerdasy HI; Ibrahim ME Can J Physiol Pharmacol; 2017 Dec; 95(12):1433-1441. PubMed ID: 28759733 [TBL] [Abstract][Full Text] [Related]
14. The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. Jorgačević B; Vučević D; Đuričić I; Šobajić S; Mladenović D; Vesković M; Vukićević RJ; Radosavljević T Chem Phys Lipids; 2017 Apr; 204():85-93. PubMed ID: 28363784 [TBL] [Abstract][Full Text] [Related]
15. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402 [TBL] [Abstract][Full Text] [Related]
16. Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model. Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27928909 [TBL] [Abstract][Full Text] [Related]